Premium
Identifying New Targets And Biomarkers For Nutritional Interventions With Global Metabolomics
Author(s) -
Karoly Edward
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.lb253
Subject(s) - metabolomics , context (archaeology) , biomarker discovery , biomarker , translational research , psychological intervention , computational biology , microbiome , medicine , bioinformatics , prebiotic , biology , proteomics , microbiology and biotechnology , genetics , paleontology , psychiatry , gene
In order to devise and develop the nutritional interventions of the future preclinical research aims to approximate an expected effect in humans to define biomarkers, targets, or the efficacy of an intervention. Clinical research aims to elucidate the same type of information in the more relevant, but less controlled, scenario. The information converges around translational science. The use of metabolomics for translational science is increasing; particularly in nutrition research. In nutrition research metabolomics has even greater relevance since, in addition to accounting for genetics, it can account for microbiota and diet/lifestyle/environmental influences. Hence, it is valuable for understanding how exogenous treatments (dietary, prebiotic, probiotic) influence the host in the context of all of these inputs. Further, due to the conservation of metabolism, the biomarkers are highly translatable, further increasing the utility of metabolomics in translational studies. Illustrating this will be recent results in which new targets (microbiota‐related, endogenous metabolic targets) and intervention strategies (probiotics, supplements) have been elucidated in preclinical studies using metabolomics. In the preclinical realm the metabolic biomarkers are often used to hone‐in on a target. In clinical studies, metabolomic biomarkers are also used to monitor efficacy, compliance and pharmacokinetics. Highlighting the inception of the use of these types of clinical biomarkers will be recent biomarker discoveries in clinical cohorts.